Carregant...

Scientific rationale for the possible inhaled corticosteroid intraclass difference in the risk of pneumonia in COPD

Inhaled corticosteroids (ICSs) treatment combined with long-acting β(2)-adrenoceptor agonists (LABAs) reduces the risk of exacerbations in COPD, but the use of ICSs is associated with increased incidence of pneumonia. There are indications that this association is stronger for fluticasone propionate...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Int J Chron Obstruct Pulmon Dis
Autors principals: Janson, Christer, Stratelis, Georgios, Miller-Larsson, Anna, Harrison, Tim W, Larsson, Kjell
Format: Artigo
Idioma:Inglês
Publicat: Dove Medical Press 2017
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5654780/
https://ncbi.nlm.nih.gov/pubmed/29089754
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S143656
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!